Epiomic Epidemiology Series: Alpha-1 Anti-Trypsin Deficiency Forecast in 9 Major Markets 2016-2026

August 2016 | 36 pages | ID: E2B7C23250AEN
Black Swan Analysis limited

Abstracts

Alpha-1 Anti-Trypsin (AAT) is an enzyme belonging to the serpin super family, and is also referred to as alpha-1 proteinase inhibitor (A1PI) because it inhibits a wide variety of proteases. AAT protects tissues from enzymes of inflammatory cells, especially neutrophil elastase protein. In its absence (such as in alpha 1-anti-trypsin deficiency), neutrophil elastase is free to break down elastin, which contributes to the elasticity of the lungs. This results in respiratory complications such as COPD (chronic obstructive pulmonary disease) in adults and cirrhosis of the liver in adults or children.

Alpha-1 Anti-Trypsin deficiency (AATD) is an inherited, rare condition that causes a complete or partial reduction in activity of Alpha-1 Anti-Trypsin (AAT) in the blood and lungs which leads to the deposit of excessive abnormal A1AT protein in liver cells.

This report provides the current prevalent population for Alpha-1 Anti-Trypsin across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Alpha-1 Anti-Trypsin have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Key underlying pathologies linked with developing Alpha-1 Anti-Trypsin include:

• Cirrhosis
• COPD
• Lung Cancer
• Asthma
• Panniculitis
• Systemic Vasculitis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in the global Alpha-1 Anti-Trypsin market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Alpha-1 Anti-Trypsin and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on the Alpha-1 Anti-Trypsin prevalent population.
• Identify sub-populations within Alpha-1 Anti-Trypsin which require treatment.
• Gain an understanding of the specific markets that have the largest number of Alpha-1 Anti-Trypsin patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key comorbid conditions/Features associated with the disease
Methodology for quantification of patient numbers
Top-line prevalence for Alpha-1 Antitrypsin Deficiency
Features of AATD patients
  Pi Phenotype
  Clinical Manifestations of AATD
Abbreviations used in the report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Tables

LIST OF TABLES

Prevalence of AATD, total (000s)
Prevalence of AATD, males (000s)
Prevalence of AATD, females (000s)
Protease inhibitor (Pi) phenotype of AATD patients, total (000s)
AATD patients with Cirrhosis, total (000s)
AATD patients with COPD, total (000s)
AATD patients with Lung Cancer, total (000s)
AATD patients with Asthma, total (000s)
AATD patients with Panniculitis, total (000s)
AATD patients with Systemic Vasculitis, total (000s)
Abbreviations and Acronyms used in the report
USA Prevalence of AATD by 5-yr age cohort, males (000s)
USA Prevalence of AATD by 5-yr age cohort, females (000s)
France Prevalence of AATD by 5-yr age cohort, males (000s)
France Prevalence of AATD by 5-yr age cohort, females (000s)
Germany Prevalence of AATD by 5-yr age cohort, males (000s)
Germany Prevalence of AATD by 5-yr age cohort females (000s)
Italy Prevalence of AATD by 5-yr age cohort, males (000s)
Italy Prevalence of AATD by 5-yr age cohort, females (000s)
Spain Prevalence of AATD by 5-yr age cohort, males (000s)
Spain Prevalence of AATD by 5-yr age cohort, females (000s)
UK Prevalence of AATD by 5-yr age cohort, males (000s)
UK Prevalence of AATD by 5-yr age cohort, females (000s)
Brazil Prevalence of AATD by 5-yr age cohort, males (000s)
Brazil Prevalence of AATD by 5-yr age cohort, females (000s)
Japan Prevalence of AATD by 5-yr age cohort, males (000s)
Japan Prevalence of AATD by 5-yr age cohort, females (000s)
India Prevalence of AATD by 5-yr age cohort, males (000s)
India Prevalence of AATD by 5-yr age cohort, females (000s)